 | | Vol. 10.41 – 18 October, 2022 |
| |
|
|
| Investigators established a platform technology that exploits hapten-peptide conjugates generated by covalent inhibitors to create distinct neoantigens that selectively mark cancer cells.
[Cancer Discovery] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists developed Slide-TCR-seq, a 10-μm-resolution method, to sequence whole transcriptomes and T cell receptors within intact tissues.
[Immunity] |
|
|
|
| By elucidating the transcriptome dynamics of tumor-associated macrophages with single-cell resolution, investigators discovered a phenomenon “macrophage to neuron-like cell transition” for directly promoting tumoral neurogenesis.
[Science Advances] |
|
|
|
| Researchers showed that in a mouse melanoma model, in the tumor-draining lymph nodes rather than in the tumors themselves, stem-like CD8+ T cells differentiate into TRMs in a TGF-β and tumor antigen dependent manner.
[Nature Communications] |
|
|
|
| Scientists showed single-cell transcriptomics and functional analyses of the myeloid cell lineage in patients with non-medullary thyroid carcinoma and multinodular goiter, before and after treatment with radioactive iodine compared to healthy controls.
[Nature Communications] |
|
|
|
| Exome- and RNA sequencing as well as in silico HLA-binding predictions to autologous HLA molecules were used to identify candidate neopeptides.
[Clinical Cancer Research] |
|
|
|
| Scientists identified tumor microenvironment-specific SPP1-expressing macrophages with altered metabolism features, foam cell characteristics and increased activity in extracellular matrix organization.
[Clinical Cancer Research] |
|
|
|
| Researchers studied the genetic and transcriptomic make-up of the antigen presentation complexes in a large cohort of patients with idiopathic aplastic anemia and paroxysmal nocturnal hemoglobinuria by using single-cell RNA, high throughput DNA sequencing and single nucleotide polymorphism-array platforms.
[Leukemia] |
|
|
|
| Anti-citrullinated protein antibodies-expressing B cells derived from peripheral blood of seven Epstein-Barr virus (EBV)-seropositive rheumatoid arthritis (RA) patients, and synovial fluid of one additional EBV-seropositive RA patient, were isolated by flow cytometry.
[Arthritis Research & Therapy] |
|
|
|
| Release profiles of chlormethine (CL) from the gel and a compounded ointment-based 0.016% CL formulation were compared via in vitro release testing, utilizing static diffusion cells, a pseudo-infinite dose, and polytetrafluoroethylene membranes, over five hours.
[Dermatology and Therapy] |
|
|
|
| Researchers investigated the analgesic effect of combined dexmedetomidine and thoracic paravertebral nerve block on gastric cancer patients undergoing open gastrectomy.
[Immunopharmacology and Immunotoxicology] |
|
|
|
| 15 hub genes were identified, among which inducible T cell co‑stimulator was indicated to serve a role in the most pivotal immunity pathways. pSS was markedly associated with inflammatory pathways.
[Molecular Medicine Reports] |
|
|
|
| The Cancer Genome Atlas, GTEx data, and human protein atlas were employed to assess the correlation between the SYDE2 expression, clinical data, and overall survival in clear cell renal cell carcinoma (ccRCC) patients.
[Heliyon] |
|  |
|
|
|
| Research and clinical trials over the past few decades have elucidated the mechanisms underlying immunotherapy-induced tolerance, involving a reduction of allergen-specific T helper 2 cells, an induction of regulatory T and B cells, and production of IgG and IgA ‘blocking’ antibodies.
[Nature Reviews Immunology] |
|
|
|
| The authors provide a comprehensive overview of the current status of cellular immunotherapy for medullablastoma, from fundamental in vitro research to in vivo models and (ongoing) clinical trials.
[Neuro-Oncology] |
|
|
|
|
| Attralus, Inc. announced that the first subject has been dosed in the Phase I clinical trial of AT-02, the company’s lead pan-amyloid removal therapeutic. The clinical trial is enrolling both healthy volunteers and patients with systemic amyloidosis.
[Attralus, Inc.] |
|
|
|
| Eucure Biopharma Co., Ltd. announced that the company has entered into a worldwide licensing agreement with Syncromune, Inc. for the development and commercialization of intratumoral immunotherapies along with Syncromune’s Syncrovax™ technology.
[Eucure (BusinessWire, Inc.)] |
|
|
|
|
| December 5 – 7, 2022
Virtual |
|
|
|
|
|
| | University College London – London, England, United Kingdom |
|
|
|
| | Luxembourg Institute of Health – Luxembourg, Luxembourg |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | Blood Centre of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | CancerCare Manitoba Research Institute – Winnipeg, Manitoba, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
